Johnson & Johnson Invests $1 Billion in Firefly Bio to Boost KRAS Inhibitor Portfolio
In a significant move to enhance its oncology pipeline, Johnson & Johnson has announced the acquisition of Firefly Bio for $1 billion, focusing on KRAS inhibitors.
Editorial Staff 14 days ago